Variant Synonymizer: Platform to identify mutations defined in different ways is available now!

VarSy

Over 2,000 gene–disease validation summaries are now available—no login required!

Browse Summaries

HPRT1 – Gout

HPRT1 encodes hypoxanthine-guanine phosphoribosyltransferase, a key enzyme in purine salvage. Hemizygous loss-of-function in males and carrier status in females leads to overproduction of uric acid, manifesting as hyperuricemia and gout with an X-linked recessive inheritance pattern.

Genetic evidence arises from nine unrelated probands (PMID:10451080,15536609,15334740,15862284,26073243,27288985,9868957,1483694,17309125) presenting with gout or hyperuricemia caused by distinct HPRT1 mutations. Variants include missense substitutions (e.g., c.152G>A (p.Arg51Gln) and c.206A>T), frameshifts and splicing defects. One representative hypomorphic allele, c.481G>T (p.Ala161Ser), was identified in a patient with severe tophaceous gout refractory to allopurinol (PMID:27288985).

Segregation analysis in a Taiwanese aboriginal pedigree demonstrated the HPRT(Tsou) variant (c.152G>A (p.Arg51Gln)) co-segregating with hyperuricemia in ten affected male and female relatives across two generations (PMID:10451080).

The variant spectrum includes six missense mutations, four novel point mutations in exon 2 or exon 3, and at least two splice-site defects. Clinical severity correlates inversely with residual enzyme activity, with partial deficiencies causing gout and near-complete loss resulting in Lesch-Nyhan syndrome.

Functional assays in erythrocytes and lymphocytes show HPRT activity reduced to 5–30% of normal in gout patients, confirming haploinsufficiency as the pathogenic mechanism and correlating with increased serum urate levels (PMID:15536609,15334740,27288985).

A regulatory defect without coding region mutation has been reported (normal HPRT coding but reduced activity), highlighting non-coding mechanisms (PMID:15862284). Overall, the evidence supports a strong X-linked recessive association between HPRT1 and gout.

Key take-home: Screening for HPRT1 variants in male patients with early-onset or refractory gout can guide diagnosis, management, and genetic counseling.

References

  • The Journal of Rheumatology • 1999 • Identification of a new single nucleotide substitution on the hypoxanthine-guanine phosphoribosyltransferase gene (HPRT(Tsou)) from a Taiwanese aboriginal family with severe gout. PMID:10451080
  • Metabolism: Clinical and Experimental • 2004 • Identification of a new point mutation in hypoxanthine phosphoribosyl transferase responsible for hyperuricemia in a female patient. PMID:15536609
  • Journal of Inherited Metabolic Disease • 2004 • Kelley-Seegmiller syndrome due to a new variant of the hypoxanthine-guanine phosphoribosyltransferase (I136T) encoding gene (HPRT Marseille). PMID:15334740
  • Molecular Genetics and Metabolism • 2005 • Normal HPRT coding region in a male with gout due to HPRT deficiency. PMID:15862284
  • Clinica Chimica Acta • 2016 • Genetic background of uric acid metabolism in a patient with severe chronic tophaceous gout. PMID:27288985

Evidence Based Scoring (AI generated)

Gene–Disease Association

Strong

Nine unrelated probands (PMID:10451080,15536609,15334740,15862284,26073243,27288985,9868957,1483694,17309125), segregation in ten relatives in one kindred (PMID:10451080)

Genetic Evidence

Strong

Nine independent HPRT1 mutations in probands with gout, segregation across two generations, and variant spectrum including missense and splice defects

Functional Evidence

Moderate

Partial HPRT enzyme activity (5–30% of normal) in patient erythrocytes and lymphocytes correlates with hyperuricemia (PMID:15536609,15334740,27288985)